Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 1, 2016, Pages 194-200

  Mooranian, Armin ^a   Negrulj, Rebecca ^a   Arfuso, Frank ^b   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

Artificial cell microencapsulation; Bile acids; Cell viability; Diabetes; Islet cells

Indexed keywords

AMINO ACIDS; BODY FLUIDS; CYTOLOGY; EFFICIENCY; MEDICAL PROBLEMS; MICROENCAPSULATION; MICROSTRUCTURE; MORPHOLOGY; SODIUM ALGINATE; STABILITY; SWELLING; ZETA POTENTIAL;

ARTIFICIAL CELL; BILE ACID; CELL VIABILITY; ISLET CELLS; PANCREATIC BETA CELLS; POTENTIAL BENEFITS; SWELLING CHARACTERISTICS; URSODEOXYCHOLIC ACID;

CELLS;

ALGINIC ACID; BILE ACID; POLYORNITHINE; URSODEOXYCHOLIC ACID; GLUCURONIC ACID; HEXURONIC ACID; MICROCAPSULE; PEPTIDE;

ARTICLE; ARTIFICIAL CELL; CELL COUNT; CELL VIABILITY; DIABETES MELLITUS; HUMAN; HUMAN CELL; MICROCAPSULE; MICROENCAPSULATION; MICROSCOPY; PANCREAS ISLET BETA CELL; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; ZETA POTENTIAL; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG FORMULATION; IMMOBILIZED CELL; MECHANICAL STRESS; METABOLISM; PHYSIOLOGY; PROCEDURES; RAT; STATIC ELECTRICITY;

ALGINATES; ANIMALS; CAPSULES; CELL LINE; CELL SURVIVAL; CELLS, IMMOBILIZED; DRUG COMPOUNDING; GLUCURONIC ACID; HEXURONIC ACIDS; INSULIN-SECRETING CELLS; PEPTIDES; RATS; STATIC ELECTRICITY; STRESS, MECHANICAL; URSODEOXYCHOLIC ACID;

EID: 84971597894     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2014.934457     Document Type: Article

References (41)

1. Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golocorbin-Kon S, Mikov I, Mikov M. 2009. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 34: 43-50.
2. Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. 2012. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 37: 99-108.
3. Al-Salami H, Butt G, Tucker I, Mikov M. 2008. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30: 107-113.
4. Awasthi R, Kulkarni GT. 2013. Development of novel gastroretentive drug delivery system of gliclazide: hollow beads. Drug Dev Ind Pharm. 40: 1-11.
5. Beck J, Angus R, Madsen B, Britt D, Vernon B, Nguyen KT. 2007. Islet encapsulation: strategies to enhance islet cell functions. Tissue Eng. 13: 589-599.
6. Bhatia SR, Khattak S F, Roberts SC. 2005. Polyelectrolytes for cell encapsulation. Curr Opin Colloid Interface Sci. 10: 45-51.
7. Calasan J, Al-Salami H, Mikov M. 2012. Bile acids and probiotics could help treating diabetes. FEBS J. 279: 267-267.
8. Claiborn KC, Stoffers DA. 2008. Toward a cell-based cure for diabetes: advances in production and transplant of beta cells. Mt Sinai J Med. 75: 362-371.
9. Codario R. 2011. Pathophysiology of Type-2 diabetes In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Totowa, NJ: Humana Press, pp. 1-14.
10. de Vos P, de Haan BJ, Kamps JA, Faas MM, Kitano T. 2007. Zeta-potentials of alginate-PLL capsules: a predictive measure for biocompatibility? J Biomed Mater Res A. 80: 813-819.
11. Dusseault J, Leblond FA, Robitaille R, Jourdan G, Tessier J, Ménard M, et al. 2005. Microencapsulation of living cells in semi-permeable membranes with covalently cross-linked layers. Biomaterials. 26: 1515-1522.
12. Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, et al. 1993. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Dig Dis Sci. 38: 1291-1296.
13. Harlan DM, Rother KI, Robertson R. 2004. Islet transplantation as a treatment for diabetes. N Engl J Med. 350: 2104.
14. Jiin WY 2000. Development of new polycations for cell encapsulation with alginate. Mater Sci Eng. 1: 59-63.
15. Lalic-Popovic M, Vasović V, Milijašević B, Goločorbin-Kon S, Al-Salami H, Mikov M. 2013. Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. J Diabetes Res. 2013: 598603.
16. Malisova L, Kováčová Z, Koc M, Kračmerová J, Stich V, Rossmeislová L. 2013. Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One. 8: e82086.
17. Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, et al. 1998. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 31: 111-118.
18. Martinez-Moya P, Romero-Calvo I, Requena P, Hernández-Chirlaque C, Aranda CJ, González R, et al. 2013. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 15: 372-380.
19. Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP. 2008. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 33: 137-142.
20. Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S, Fawcett JP. 2006. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5beta-cholanate (MKC) in diabetic rat. FEBS J. 273: 210-210.
21. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. 2014a. A complex microencapsulated system: a platform for optimised oral delivery of antidiabetic drugbile acid formulations. Pharm Dev Technol. (Epub ahead of print).
22. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. 2014b. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov 9: 150-157.
23. Nafea EH, Marson A, Poole-Warren LA, Martens PJ. 2011. Immunoisolating semi-permeable membranes for cell encapsulation: focus on hydrogels. J Control Release. 154: 110-122.
24. Negrulj R, Mooranian A, Al-Salami H. 2013. Potentials and limitations of bile acids in Type 2 diabetes mellitus: Applications of microen-capsulation as a novel oral delivery system. J Endocrinol. Diabetes Mellitus. 1: 49-59.
25. Nolan CJ, Damm P, Prentki M. 2011. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 378: 169-181.
26. Pal D, Nayak AK. 2011. Development, optimization, and anti-diabetic activity of gliclazide-loaded alginate-methyl cellulose mucoadhe-sive microcapsules. AAPS PharmSciTech. 12: 1431-1441.
27. Pal D, Nayak AK. 2012. Novel tamarind seed polysaccharide-alginate mucoadhesive microspheres for oral gliclazide delivery: in vitro-in vivo evaluation. Drug Deliv. 19: 123-131.
28. Puri S, Hebrok M. 2012. Diabetic beta cells: to be or not to be? Cell. 150: 1103-1104.
29. Rokstad AM, Lacík I, de Vos P, Strand BL. 2013. Advances in biocompatibility and physico-chemical characterization of micro-spheres for cell encapsulation. Adv Drug Deliv Rev. 67-68: 111-130.
30. Rokstad AM, Lacík I, de Vos P, Strand BL. 2014. Advances in biocompatibility and physico-chemical characterization of micro-spheres for cell encapsulation. Adv Drug Deliv Rev. 67-68C: 111-130.
31. Rudi J, Schlenker T, Raedsch R, Waldherr R, Zorn M, Stremmel W. 1995. Effect of ursodeoxycholic acid on biochemical parameters, hepatocyte proliferation and liver histology in galactosamine hepatitis in the rat. Res Exp Med (Berl). 195: 309-315.
32. Schneider S, Feilen PJ, Slotty V, Kampfner D, Preuss S, Berger S, et al. 2001. Multilayer capsules: a promising microencapsulation system for transplantation of pancreatic islets. Biomaterials. 22: 1961-1970.
33. Stumvoll M, Goldstein BJ, van Haeften TW 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 365: 1333-1346.
34. Takka S, Cali AG. 2012. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol. 17: 23-29.
35. Taylor R. 2013. Type 2 diabetes: etiology and reversibility. Diabetes Care. 36: 1047-1055.
36. Thanos CG, Bintz BE, Emerich DF. 2007a. Stability of alginatepolyornithine microcapsules is profoundly dependent on the site of transplantation. J Biomed Mater Res A. 81: 1-11.
37. Tanos CG, Calafiore R, Basta G, Bintz BE, Bell WJ, Hudak J, et al. 2007b. Formulating the alginate-polyornithine biocapsule for prolonged stability: evaluation of composition and manufacturing technique. J Biomed Mater Res A. 83: 216-224.
38. Uludag H, Sefton MV. 1990. Colorimetric assay for cellular activity in microcapsules. Biomaterials. 11: 708-712.
39. Urbanska AM, Bhathena J, Prakash S. 2007. Live encapsulated Lactobacillus acidophilus cells in yogurt for therapeutic oral delivery: preparation and in vitro analysis of alginate-chitosan microcapsules. Can J Physiol Pharmacol. 85: 884-893.
40. Weir GC 2013. Islet encapsulation: advances and obstacles. Diabetologia. 56: 1458-1461.
41. Wong H, Chang TM. 1991. The microencapsulation of cells within alginate poly-L-lysine microcapsules prepared with the standard single step drop technique: histologically identified membrane imperfections and the associated graft rejection. Biomater Artif Cells Immobilization Biotechnol. 19: 675-686.